{"id":"et-26","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, ET-26 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"ET-26 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:39.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06682546","phase":"PHASE2","title":"A Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride in Gastroscopy/Colonoscopy","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2024-11-15","conditions":"Gastroscopy, Colonoscopy","enrollment":78},{"nctId":"NCT06858852","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy","status":"NOT_YET_RECRUITING","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2025-03","conditions":"Gastroscopy, Colonoscopy","enrollment":270},{"nctId":"NCT06822166","phase":"PHASE1","title":"Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-04","conditions":"Interaction Drug Food","enrollment":68},{"nctId":"NCT06822153","phase":"PHASE1","title":"Clinical Trial of the Effect of Methoxyethyl Etomidate Hydrochloride on the QT Interval of the Heart","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-11-09","conditions":"QT Interval, Variation in","enrollment":18},{"nctId":"NCT06822114","phase":"PHASE1","title":"Substance Balance Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-07-17","conditions":"Pharmacokinetics","enrollment":6},{"nctId":"NCT06764147","phase":"PHASE1","title":"Safety and Pharmacokinetics/ Pharmacodynamics of Methoxyethyl Etomidate Hydrochloride in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-25","conditions":"Healthy Elderly Subjects","enrollment":16},{"nctId":"NCT06747520","phase":"PHASE1","title":"Phase 1 Renal Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-11-30","conditions":"Renal Insufficiency","enrollment":24},{"nctId":"NCT06203431","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Methoxyetomidate Hydrochloride for Injection (ET-26) for the Induction of General Anesthesia in Elective Surgery Subjects","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-10-11","conditions":"Anesthesia Induction","enrollment":270},{"nctId":"NCT06176716","phase":"PHASE1","title":"Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-06","conditions":"Hepatic Insufficiency","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ET-26","genericName":"ET-26","companyName":"Ahon Pharmaceutical Co., Ltd.","companyId":"ahon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ET-26 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}